Challenges in the Development of Effective Peptide Vaccines for Cancer

This publication has 72 references indexed in Scilit:

• A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk Melanoma
  Journal of Immunotherapy, 1999
• Identification of GP100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primaryin vitro immunization with peptide-pulsed dendritic cells
  International Journal of Cancer, 1998
• CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
  European Journal of Immunology, 1997
• Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs
  Immunology Today, 1996
• Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules
  Human Immunology, 1996
• Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevance
  Immunology Today, 1995
• Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?
  Immunology Today, 1995
• Direct analysis of tumor-associated peptide antigens
  Current Opinion in Immunology, 1994
• T-cell adjuvants
  International Journal of Immunopharmacology, 1994
• T-cell immunotherapy of cancer
  Research in Immunology, 1991